Australian Committee Recommends Wider Access to Immunotherapy Treatments
The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended expanding the listing of nivolumab (Opdivo®) and ipilimumab (Yervoy®) on the Pharmaceutical Benefits Scheme (PBS) to cover a broader range of advanced and metastatic cancers.
- Expansion of listings for re-treatment of the same cancer
- Longer use for patients likely to respond to treatment
- Removal of the "once in a lifetime" restriction for patients with multiple cancer types
- Extended access for patients with rare cancers
Author's summary: Australian committee recommends broader access to immunotherapy.